Sanofi has discontinued development of amlitelimab for atopic dermatitis following a pipeline review. The decision was based on an assessment of efficacy and safety data that indicated no meaningful improvement over current treatments. This move affects a key immunology asset and will influence how Sanofi sets its future research and development priorities. Atopic dermatitis is an important area for many drug makers given ongoing patient needs and existing biologic therapies, and this decision removes one potential future option from Sanofi's immunology portfolio.
Sanofi SASanofi discontinues amlitelimab for atopic dermatitis after pipeline review, removing a key immunology asset.